Section Arrow
GPCR.NASDAQ
- Structure Therapeutics
Quotes are at least 15-min delayed:2024/06/25 01:49 EDT
Last
 43.69
-1.88 (-4.13%)
Day High 
45.68 
Prev. Close
45.57 
1-M High
62.74 
Volume 
1.40M 
Bid
43.05
Ask
44.44
Day Low
43.01 
Open
45.14 
1-M Low
33.56 
Market Cap 
2.60B 
Currency USD 
P/E -- 
%Yield
10-SMA 49.63 
20-SMA 46.59 
50-SMA 41.19 
52-W High 75.0167 
52-W Low 25.57 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.25/--
Enterprise Value
2.60B
Balance Sheet
Book Value Per Share
7.53
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.3662-0.0582-13.71%-- 
REVBRevelation Biosciences2.37+0.26+12.32%-- 
GLYCGlycoMimetics0.2648+0.0075+2.91%-- 
ALTAltimmune7.135+0.725+11.31%-- 
MBIOMustang Bio0.5703+0.015+2.70%-- 
Quotes are at least 15-min delayed:2024/06/25 01:49 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.